Pursuing new possibilities in haematological disorders

Haemophilia is a serious chronic disease that impairs the body's blood clotting process and can result in joint damage, pain, internal bleeding and death. The two main types of haemophilia, haemophilia A and haemophilia B, are commonly inherited genetic disorders with defects in blood clotting factors VIII and IX respectively1. Currently, most haemophilia treatments must be infused directly into the bloodstream on a frequent basis. Our scientists are exploring innovative long-acting and subcutaneous solutions, which are aimed at reducing the current treatment burden and improving clinical outcomes, and will be complemented by research into oral treatments and gene therapy.

 

Do you want to know more about living with Haemophilia?


450000 people

Around 450,000 people live with
haemophilia A or B2,3

haemophilia

Of these people, 50% live
in constant pain4


haemophilia stephanie

Meet the scientist

“This is my life’s work. Period. I first worked with people with haemophilia during the AIDS epidemic in the 1980s. Today, we have recombinant products with high safety available for treatment, and we’re working on longer-acting molecules and subcutaneous treatments.”

Stephanie Seremetis 
Global Chief Medical Officer for Haemophilia, 
Princeton, USA
LinkedIn profile


Novo Nordisk Heamophilia foundation

Collaboration to improve access to care

Since 2005, the Novo Nordisk Haemophilia Foundation, a non-profit organisation, has been working to improve access to care for people with haemophilia and related bleeding disorders in the developing world. Focused on improving haemophilia diagnosis and education, the foundation supports awareness activities and the development of strategic partnerships.

 

Visit Novo Nordisk Haemophilia Foundation


Innovating to change patients’ lives

We are always seeking partnerships that focus on novel targets and innovative compounds and technologies that address the unmet medical needs of people with haemophilia and other rare and serious haematological disorders. We are currently seeking to partner with academia and other pharmaceutical companies on:

  • Novel bypassing agents for prophylaxis in haemophilia
  • Cell and gene-based therapy approaches
  • Clinical assets in haematological disorders

 

Explore partnering opportunities

haemophilia innovating

Follow our progress

Explore our scientists’ work on new haemophilia treatments.

 


Recent publications

publications thumbnail

To contribute to the scientific community in our areas of expertise, we take pride in publishing our scientists’ new findings. Visit the library to review some of their recent work.

 

Explore our publications

 

 

A network that changes lives

Clinical trials thumbnail

Novo Nordisk conducts clinical trials in over 50 countries worldwide, and we have a high retention rate among our trial participants.



Our clinical trials

 

 

References